Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 324 |
| Active Pipeline (Recruiting Now) | 128 (66) |
| Completed vs Stopped Early | 150 / 46 (14.2%) |
| Median Closed Actual Enrollment | 184 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 189 (19 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Washington University and Siteman Cancer Center | Saint Louis, MO | 36 |
| University of Chicago Medicine | Chicago, IL | 34 |
| Ohio State University Comprehensive Cancer Center | Columbus, OH | 34 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06575192 | Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants | Phase III | RECRUITING |
| NCT07196644 | A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic | Phase II | RECRUITING |
| NCT07059845 | A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansin | Phase II | RECRUITING |
| NCT06548542 | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease | Phase II | RECRUITING |
| NCT06890338 | A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Di | Phase II | RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the AbbVie Interactive Dossier, benchmark peers in Immunology, Rheumatology, and Dermatology, or review the Healthcare Price & Patent Cliff Crosswalk.